<DOC>
	<DOCNO>NCT01498003</DOCNO>
	<brief_summary>Periprocedural myonecrosis infarction associate short , intermediate , long term adverse outcome . Previous study indicate 12.6 % patient suffer peri-procedural CK-MB rise overlap use drug-eluting stent long coronary lesion . Here investigator hypothesize peri-procedural use tirofiban could reduce occurrence periprocedural infarciton elective patient long coronary lesion treat overlap use drug-eluting stent .</brief_summary>
	<brief_title>Tirofiban Stenting Long Coronary Lesion</brief_title>
	<detailed_description>According result 12.6 % occurrence peri-procedural myocardial infarction long stent implantation previous report [ International Journal Cardiology 2009 ; 134 : 231-237 ] , investigator hypothesize 50 % reduction peri-procedural MI use tirofiban . Three hundred sixty-nine patient group need reach 80 % power Î± 0.05 .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>Age 18y~80y , symptomatic coronary disease At least one lesion length 40mm treated overlap drugeluting stent major epicardial coronary vessel Aspirin clopidogrel intolerance Lesions length less 40mm , overlap stent length le 40mm Bifurcation lesion need treat two stent Patients acute coronary syndrome elevate baseline cardiac enzyme ( CKMB ) Left ventricular ejection fraction le 0.35 Baseline estimate GFR le 30 Estimated life time le one year Refuse sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>coronary disease</keyword>
	<keyword>stent</keyword>
	<keyword>thrombosis</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>prognosis</keyword>
</DOC>